[EN] PHENYL mTORC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE MTORC PHÉNYLE ET LEURS UTILISATIONS
申请人:NAVITOR PHARM INC
公开号:WO2018089433A1
公开(公告)日:2018-05-17
The present invention provides compounds, compositions thereof, and methods of using the same.
本发明提供了化合物、其组合物以及使用相同的方法。
[EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EZH2 ET LEURS UTILISATIONS
申请人:DANA FARBER CANCER INST INC
公开号:WO2016073956A1
公开(公告)日:2016-05-12
The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1and/or EZH2 inhibitors.
Sodium bis(2-methoxyethoxy)aluminum hydride in reactions with 3-cyano-6-methylpyridine-2(1H)-thione and 3-cyano-6-methyl(4,6-dimethyl)-2-methylthiopyridines
作者:A. A. Zubarev、V. K. Zav"yalova、V. P. Litvinov
DOI:10.1023/b:rucb.0000035647.06853.80
日期:2004.3
The reactions of sodiumbis(2-methoxyethoxy)aluminumhydride with 3-cyano-6-methylpyridine-2(1H)-thione and 3-cyano-6-methyl-2-methylthiopyridine afforded 3-aminomethyl-6-methylpyridine-2(1H)-thione and azomethine of the pyridine series, respectively. The corresponding reaction with 3-cyano-4,6-dimethyl-2-methylthiopyridine gave rise to azomethine, substituted 3-aminomethylpyridine, and substituted
[EN] USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD)<br/>[FR] UTILISATION DE COMPOSITIONS MODULANT LA STRUCTURE DE LA CHROMATINE CONTRE LA MALADIE DU GREFFON CONTRE L'HÔTE (GVHD)
申请人:DANA FARBER CANCER INST INC
公开号:WO2016073903A1
公开(公告)日:2016-05-12
In some aspects, the instant disclosure relates to methods of treating chronic graft versus host disease (cGVHD). In some embodiments, the method comprises administering to a subject in need thereof a EZH2 inhibitor, a Bcl6 inhibitor and/or BRD4 inhibitor. The present disclosure is based, at least in part, on the discovery that enhancer of zeste homolog 2 (EZH2) inhibitors, B-cell lymphoma 6 protein (Bcl6) inhibitors and/or bromodomain-containing protein 4 (BRD4) inhibitors can be used to treat chronic graft versus host disease (cGVHD).
作者:A. A. Zubarev、V. K. Zav’yalova、A. M. Shestopalov
DOI:10.1007/s11172-011-0082-2
日期:2011.3
A reaction of alkyl bromoacetates with substituted 3-cyano-2-methylthiopyridines in the presence of zinc dust furnishes 3-amino-3-(2-methylthiopyridin-3-yl)propenoic esters. Their hydrolysis under mild conditions leads to 3-(2-methylthiopyridin-3-yl)-3-oxopropionic esters. The latter were used in the synthesis of pyridine-substituted pyrazolones.